High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography

Vaccine

Volumn 34, Issue 10, 2016, Pages 1259-1267

  Ladd Effio, Christopher ^a   Oelmeier, Stefan A ^a,b   Hubbuch, Jürgen ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Aggregates; High throughput analytics; Papillomavirus; Process analytical technology; Size exclusion HPLC; Virus like particle vaccines

Indexed keywords

HEPATITIS B CORE ANTIGEN; RECOMBINANT PROTEIN; THYROGLOBULIN; URACIL; VIRUS LIKE PARTICLE VACCINE;

ARTICLE; ENTEROVIRUS 71; FREEZE THAWING; PAPILLOMAVIRIDAE; PHOTON CORRELATION SPECTROSCOPY; PRECIPITATION; PRIORITY JOURNAL; SIZE EXCLUSION CHROMATOGRAPHY; TRANSMISSION ELECTRON MICROSCOPY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUS LIKE AGENT; ENTEROVIRUS A; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN PARVOVIRUS B19; IMMUNOLOGY; ISOLATION AND PURIFICATION; POLYOMAVIRUS;

CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENTEROVIRUS A, HUMAN; HEPATITIS B CORE ANTIGENS; HIGH-THROUGHPUT SCREENING ASSAYS; PARVOVIRUS B19, HUMAN; POLYOMAVIRUS; RECOMBINANT PROTEINS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84958811572     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.01.035     Document Type: Article

References (50)

1. Zeltins A. Construction and characterization of virus-like particles: a review. Mol Biotechnol 2013, 53(1):92-107. 10.1007/s12033-012-9598-4.
2. Lua L.H.L., Connors N.K., Sainsbury F., Chuan Y.P., Wibowo N., Middelberg A.P.J. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 2014, 111(3):425-440. 10.1002/bit.25159.
3. Buonaguro L., Tagliamonte M., Visciano M.L., Andersen H., Lewis M., Pal R., et al. Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration. Clin Vaccine Immunol 2012, 19(6):970-973. 10.1128/CVI.00068-12.
4. Low J.G.H., Lee L.S., Ooi E.E., Ethirajulu K., Yeo P., Matter A., et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine 2014, 32(39):5041-5048. 10.1016/j.vaccine.2014.07.011.
5. Sun Y., Carrion R., Ye L., Wen Z., Ro Y.-T., Brasky K., et al. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 2009, 383:12-21. 10.1016/j.virol.2008.09.020.
6. Vekemans J., Leach A., Cohen J. Development of the RTS,S/AS malaria candidate vaccine. Vaccine 2009, 27(Suppl 6):G67-71. 10.1016/j.vaccine.2009.10.013.
7. Middelberg A.P.J., Rivera-Hernandez T., Wibowo N., Lua L.H.L., Fan Y., Magor G., et al. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 2011, 29(41):7154-7162. 10.1016/j.vaccine.2011.05.075.
8. Klamp T., Schumacher J., Huber G., Kühne C., Meissner U., Selmi A., et al. Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases. Cancer Res 2011, 71(2):516-527. 10.1158/0008-5472.CAN-10-2292.
9. Bachmann M.F., Whitehead P. Active immunotherapy for chronic diseases. Vaccine 2013, 31(14):1777-1784. 10.1016/j.vaccine.2013.02.001.
10. Metz B., van den Dobbelsteen G., van Els C., van der Gun J., Levels L., van der Pol L., et al. Quality-control issues and approaches in vaccine development. Expert Rev Vaccines 2009, 8:227-238. 10.1586/14760584.8.2.227.
11. Ladd Effio C., Hubbuch J. Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles. Biotechnol J 2015, 10:715-727. 10.1002/biot.201400392.
12. Carrondo M.J.T., Alves P.M., Carinhas N., Glassey J., Hesse F., Merten O.W., et al. How can measurement, monitoring, modeling and control advance cell culture in industrial biotechnology?. Biotechnol J 2012, 7:1522-1529. 10.1002/biot.201200226.
13. Shi L., Sanyal G., Ni A., Luo Z., Doshna S., Wang B., et al. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci 2005, 94(7):1538-1551. 10.1002/jps.20377.
14. Zhao Q., Allen M.J., Wang Y., Wang B., Wang N., Shi L., et al. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine 2012, 8:1182-1189. 10.1016/j.nano.2012.01.007.
15. Yu Z., Reid J.C., Yang Y.-P. Utilizing dynamic light scattering as a process analytical technology for protein folding and aggregation monitoring in vaccine manufacturing. J Pharm Sci 2013, 102:4284-4290. 10.1002/jps.23746.
16. Lang R., Winter G., Vogt L., Zurcher a., Dorigo B., Schimmele B. Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation. Drug Dev Ind Pharm 2009, 35:83-97. 10.1080/03639040802192806.
17. Citkowicz A., Petry H., Harkins R.N., Ast O., Cashion L., Goldmann C., et al. Characterization of virus-like particle assembly for DNA delivery using asymmetrical flow field-flow fractionation and light scattering. Anal Biochem 2008, 376:163-172. 10.1016/j.ab.2008.02.011.
18. Pease L.F., Lipin D.I., Tsai D.-H., Zachariah M.R., Lua L.H.L., Tarlov M.J., et al. Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Biotechnol Bioeng 2009, 102:845-855. 10.1002/bit.22085.
19. Deschuyteneer M., Elouahabi A., Plainchamp D., Plisnier M., Soete D., Corazza Y., et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccine 2010, 6:407-419. 10.4161/hv.6.5.11023.
20. Yang Y., Li H., Li Z., Zhang Y., Zhang S., Chen Y., et al. Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens. Vaccine 2015, 33:1143-1150. 10.1016/j.vaccine.2015.01.031.
21. Fekete S., Beck A., Veuthey J.-L., Guillarme D. Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J Pharm Biomed Anal 2014, 101:161-173. 10.1016/j.jpba.2014.04.011.
22. Tekewe A., Connors N.K., Sainsbury F., Wibowo N., Lua L.H., Middelberg A.P. A rapid and simple screening method to identify conditions for enhanced stability of modular vaccine candidates. Biochem Eng J 2015, 100:50-58. 10.1016/j.bej.2015.04.004.
23. Schmidt U., Rudolph R., Böhm G. Mechanism of assembly of recombinant murine polyomavirus-like particles. J Virol 2000, 74:1658-1662.
24. Li Y., Bi J., Zhou W., Huang Y., Sun L., Zeng A.-P., et al. Characterization of the large size aggregation of Hepatitis B virus surface antigen (HBsAg) formed in ultrafiltration process. Process Biochem 2007, 42(3):315-319. 10.1016/j.procbio.2006.08.016.
25. Huang Y., Bi J., Zhang Y., Zhou W., Li Y., Zhao L., Su Z. A highly efficient integrated chromatographic procedure for the purification of recombinant hepatitis B surface antigen from Hansenula polymorpha. Protein Exp Purif 2007, 56:301-310. 10.1016/j.pep.2007.08.009.
26. Yu M., Zhang S., Zhang Y., Yang Y., Ma G., Su Z. Microcalorimetric study of adsorption and disassembling of virus-like particles on anion exchange chromatography media. J Chromatogr A 2015, 1388:195-206. 10.1016/j.chroma.2015.02.048.
27. Farnan D., Moreno G.T., Stults J., Becker A., Tremintin G., van Gils M. Interlaced size exclusion liquid chromatography of monoclonal antibodies. J Chromatogr A 2009, 1216:8904-8909. 10.1016/j.chroma.2009.10.045.
28. Diederich P., Hansen S.K., Oelmeier S.A., Stolzenberger B., Hubbuch J. A sub-two minutes method for monoclonal antibody-aggregate quantification using parallel interlaced size exclusion high performance liquid chromatography. J Chromatogr A 2011, 1218:9010-9018. 10.1016/j.chroma.2011.09.086.
29. Kim K., Park S., Ko K. Current status of human papillomavirus vaccines. Clin Exp Vaccine Res 2014, 3:168-175. 10.7774/cevr.2014.3.2.168.
30. Lim P.-Y., Hickey A.C., Jamiluddin M.F., Hamid S., Kramer J., Santos R., et al. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine 2015, 1-8. 10.1016/j.vaccine.2015.05.108.
31. Chandramouli S., Medina-Selby A., Coit D., Schaefer M., Spencer T., Brito L.A., et al. Generation of a parvovirus B19 vaccine candidate. Vaccine 2013, 31(37):3872-3878. 10.1016/j.vaccine.2013.06.062.
32. Ladd Effio C., Wenger L., Ötes O., Oelmeier S.a., Hubbuch J. Downstream processing of virus-like particles: single-stage and multi-stage aqueous two-phase extraction. J Chromatogr A 2015, 1383:35-46. 10.1016/j.chroma.2015.01.007.
33. Effio C.L., Hahn T., Seiler J., Oelmeier S.A., Asen I., Silberer C., Villain L., Hubbuch J. Modeling and simulation of anion-exchange membrane chromatography for purification of Sf9 insect cell-derived virus-like particles. J. Chromatogr. A 2015, 1429:142-154. 10.1016/j.chroma.2015.12.006.
34. Wiendahl M., Völker C., Husemann I., Krarup J., Staby A., Scholl S., et al. A novel method to evaluate protein solubility using a high throughput screening approach. Chem Eng Sci 2009, 64:3778-3788. 10.1016/j.ces.2009.05.029.
35. Oelmeier S., Ladd-Effio C., Hubbuch J. Alternative separation steps for monoclonal antibody purification: Combination of centrifugal partitioning chromatography and precipitation. J Chromatogr A 2013, 1319:118-126.
36. ICH Guideline Q2 Validation of analytical procedures: text and methodology 1994.
37. Erickson H.P. Size and shape of protein molecules at the nanometer level determined by sedimentation, gel filtration, and electron microscopy. Biol Proc Online 2009, 11(1):32-51. 10.1007/s12575-009-9008-x.
38. Yang R., Tang Y., Zhang B., Lu X., Liu A., Zhang Y.T. High resolution separation of recombinant monoclonal antibodies by size-exclusion ultra-high performance liquid chromatography (SE-UHPLC). J Pharm Biomed Anal 2015, 109:52-61.
39. Zhao Q., Guo H.H., Wang Y., Washabaugh M.W., Sitrin R.D. Visualization of discrete L1 oligomers in human papillomavirus 16 virus-like particles by gel electrophoresis with Coomassie staining. J Virol Methods 2005, 127:133-140. 10.1016/j.jviromet.2005.03.015.
40. Mohr J., Chuan Y.P., Wu Y., Lua L.H.L., Middelberg A.P.J. Virus-like particle formulation optimization by miniaturized high-throughput screening. Methods 2013, 60(3):248-256. 10.1016/j.ymeth.2013.04.019.
41. Liu C.-C., Guo M.-S., Lin F.H.-Y., Hsiao K.-N., Chang K.H.-W., Chou A.-H., et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 2011, 6. 10.1371/journal.pone.0020005.
42. Bernstein D.I., El Sahly H.M., Keitel W.a., Wolff M., Simone G., Segawa C., et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011, 29(43):7357-7363. 10.1016/j.vaccine.2011.07.080.
43. Jain N.K., Sahni N., Kumru O.S., Joshi S.B., Volkin D.B., Russell Middaugh C. Formulation and stabilization of recombinant protein based virus-like particle vaccines. Adv Drug Deliv Rev 2016, 10.1016/j.addr.2014.10.023.
44. Giese G., Myrold A., Gorrell J., Persson J. Purification of antibodies by precipitating impurities using Polyethylene Glycol to enable a two chromatography step process. J Chromatogr B Anal Technol Biomed Life Sci 2013, 938:14-21. 10.1016/j.jchromb.2013.08.029.
45. Cook III JC. Process for purifying human papillomavirus virus-like particles, US Patent 6,602,697 (August 5, 2003).
46. ICH Guideline Q7 Good manufacturing practice for active pharmaceutical ingredients 2000.
47. ICH Guideline Q8 Pharmaceutical development 2006.
48. Karpenko L.I., Ivanisenko V.A., Pika I.A., Chikaev N.A., Eroshkin A.M., Veremeiko T.A., et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric. Amino Acids 2000, 18:329-337.
49. Lin S.-Y., Chiu H.-Y., Chiang B.-L., Hu Y.-C. Development of EV71 virus-like particle purification processes. Vaccine 2015, 1-8. 10.1016/j.vaccine.2015.04.077.
50. Kaufmann B., Simpson A.A., Rossmann M.G. The structure of human parvovirus B19. Proc Natl Acad Sci U S A 2004, 101(32):11628-11633. 10.1073/pnas.0402992101.